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Abstract
Epithelial ovarian cancer (OvCa) is associated with high mortality and, as the majority (>75%) of
women with OvCa have metastatic disease at the time of diagnosis, rates of survival have not
changed appreciably over 30 years. A mechanistic understanding of OvCa initiation and
progression is hindered by the complexity of genetic and/or environmental initiating events and
lack of clarity regarding the cell(s) or tissue(s) of origin. Metastasis of OvCa involves direct
extension or exfoliation of cells and cellular aggregates into the peritoneal cavity, survival of
matrix-detached cells in a complex ascites fluid phase, and subsequent adhesion to the
mesothelium lining covering abdominal organs to establish secondary lesions containing host
stromal and inflammatory components. Development of experimental models to recapitulate this
unique mechanism of metastasis presents a remarkable scientific challenge and many approaches
used to study other solid tumors (lung, colon, and breast, for example) are not transferable to
OvCa research given the distinct metastasis pattern and unique tumor microenvironment. This
review will discuss recent progress in the development and refinement of experimental models to
study OvCa. Novel cellular, three-dimensional organotypic, and ex vivo models are considered and
the current in vivo models summarized. The review critically evaluates currently available genetic
mouse models of OvCa, the emergence of xenopatients, and the utility of the hen model to study
OvCa prevention, tumorigenesis, metastasis, and chemoresistance. As these new approaches more
accurately recapitulate the complex tumor microenvironment, it is predicted that new
opportunities for enhanced understanding of disease progression, metastasis and therapeutic
response will emerge.
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1 INTRODUCTION
Ovarian cancer (OvCa) continues to be a poorly understood disease with an extremely poor
prognosis. Its cell of origin is still unknown and researchers have only begun to elucidate its
molecular mechanisms. Several molecular changes have been confirmed in human tumors
and functionally characterized in cell and animal models (e.g. p53, PI3 kinase, ARID1, K-
ras, BRCA1, 2).1–6 However, no genetic alteration has, as yet, been found to be a clinically
“actionable” genetic change. One reason for the slow progress made in understanding the
biology of OvCa and translating that knowledge into substantial clinical benefits has been a
lack of clinically representative model systems that mimic the progression of the human
disease. Since the majority of women diagnosed with epithelial OvCa (>75%) have intra-
abdominal metastasis at the time of diagnosis, models that replicate the molecular events
that underlie dissemination are a crucial tool to gain the knowledge necessary for the
development of new treatments.
Several excellent reviews discuss the current knowledge of OvCa biology.1–3,7 This review
offers a comprehensive overview of experimental models available for the study of ovarian
cancer. By reviewing the current state of model systems, the hope is to stimulate discussions
on how these models may be improved, as well as provide a needed reference. The biology
of OvCa poses special challenges to the development of model systems. The disease
commonly referred to as ‘ovarian cancer’ is not a single entity, but consists of several
histological subtypes (serous, endometrioid, clear cell, and mucinous) with distinct
molecular aberrations.1,3 The site of origin for high-grade serous ovarian cancer, the major
histological subtype, is still unknown and is intensely debated. Possible sites include the
abdominal peritoneum and the fallopian tube fimbriae, as well as the ovarian surface
epithelium.7,8 Moreover, OvCa is distinct from most other solid tumors in that
hematogenous metastasis is rare.9 The initial early event in epithelial OvCa metastasis is
proteinase-mediated shedding into the peritoneal cavity.10–12 Intra-peritoneal metastatic
implants are initiated by single cells and spheroids adhering to peritoneal mesothelial cells
and anchoring in the sub-mesothelial matrix to establish secondary lesions.13–15
Accumulated peritoneal ascites (often > 500ml) contains a unique non-adherent population
of individual tumor cells and multicellular aggregates (spheroids) exposed to a set of
microenvironmental cues that promote metastatic implantation.1,13,14 Since the mortality of
OvCa is directly attributed to disseminated peritoneal metastasis, this distinctive
microenvironment provides a marked set of therapeutic challenges and necessitates research
that makes use of a suite of model systems to recapitulate specific cellular and molecular
events in metastasis.
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2 THREE-DIMENSIONAL CULTURE MODELS OF OVARIAN CANCER TO
RECAPITULATE THE TUMOR MICROENVIRONMENT
Ovarian tumors are not a solid matrix of epithelial cells, but rather a mixture of epithelial,
stromal, immune, and endothelial cells.1,3,9 This complex tumor microenvironment (TME)
includes (a) primary tumor with tumor associated stromal cells (fibroblasts, mesothelial
cells) and inflammatory cells (macrophages, leukocytes); (b) non-adherent cells suspended
in ascites with inflammatory and mesothelial cells; and (c) metastases to various parts of
peritoneal cavity that contact mesothelial cells, adipocytes, and fibroblasts at the metastatic
site.9 This heterogeneity of cell types likely impacts tumor histology, growth potential and
ability to evade chemotherapy. Optimal treatment for ovarian cancer patients consists of
tumor debulking (removing all tumors >1mm) followed by chemotherapy. As ovarian
cancer is often widely disseminated with many microscopic implants that cannot be
surgically removed, leading to disease recurrence within the first 2–3 years, there is a critical
need for a more detailed understanding of early events in (re)colonization of metastatic
implants. These experimental questions require new model systems that have been designed
to recapitulate events occurring in the OvCa TME.
While our knowledge of OvCa biology has largely been derived from experiments using
cancer cells grown in two-dimensions on plastic, studying OvCa initiation, progression and
metastasis in a three-dimensional (3D) system has many advantages. In particular, epithelial
cells grown in 3D with extracellular and/or cellular components of the TME exhibit a
number of features similar to those of cells in the clinical microenvironment. Therefore, 3D
models that incorporate extracellular matrices (ECM) and stromal cells provide an
opportunity for understanding the crosstalk between OvCa and stromal cells; for detailed
analysis of the contribution of stromal elements to cell adhesion, invasion, and nutrient
access; and to assess the influence of the TME on tumor cell survival, proliferation and
differentiation.
2.1 Ovarian cancer cells and three-dimensional matrices
Initial strategies for creating 3D cultures16,17 began with mixing OvCa cell lines or primary
cells with different forms of ECM. The ECM used was typically either a purified series of
proteins, such as collagen, or an extract derived from a more complex mixture, such as
Matrigel®. The early events that follow sub-mesothelial matrix contact are modeled by
culturing cells on top of 3D collagen gels, allowing the evaluation of changes in gene
expression that accompany metastatic anchoring [Figure 1Aa–c].2,18 Matrix penetration,
survival and proliferation within the mechanically constrained 3D matrix environment can
be modeled by seeding single cells within 3D collagen gels [Figure 1Ad–e]. Indeed,
successful growth of a metastatic aggregate requires proliferation within a mechanically
constrained matrix microenvironment, a process facilitated by the expression of matrix-
degrading proteinases such as membrane type 1 matrix metalloproteinase (MT1-MMP) that
promotes proliferation within an interstitial collagen mileu.19,20 OvCa cells grown in 3D
culture on growth factor-reduced (GFR)-Matrigel exhibit a central hypoxic region, leading
to the decreased diffusion and perfusion of drugs.21 The GFR-Matrigel OvCa model has
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been used to screen for drugs that are able to penetrate deep into the hypoxic and acidic
region of the 3D culture.22
2.2 Spheroids or multi-cellular aggregates
Ovarian cancer spheroids that range in size from 30–200 μm can be isolated from patient-
ascites23 or produced by growing OvCa cells on non-adherent plates24, spinner-flasks,25 or
by using the hanging drop culture method [Figure 1B].26 Multi-cellular aggregate formation
may facilitate metastasis, since spheroids resist anoikis and can adhere to both omentum and
exposed ECM.13,14 Adhesion of spheroids initiates a transition from a floating cell
population to a peritoneally-anchored metastatic lesion. Following adhesion to a collagen
surface, the cells acquire unique mRNA profiles that more closely resemble in vivo tumor
gene expression profiles.26
2.3 Co-culture of mesothelial with ovarian cancer cells
The main sites of OvCa metastasis are mesothelial cell-lined peritoneal surfaces, including
the peritoneum, omentum and pleural surface.15 Notably, in 1985 the first 3D peritoneal
culture was used to investigate the adhesion of primary human OvCa cells to primary human
mesothelial cells grown on a bovine corneal endothelial cell-derived extracellular matrix.27
Other 3D OvCa co-cultures followed, with cancer cell lines or primary cells grown as
monolayers on plastic or as tissue-like multi-cellular aggregates [Figure 1B], which were co-
cultured with mesothelial cell monolayers.28–33 A derivation of this strategy was the
utilization of conditioned medium secreted by mesothelial cells to monitor the influence of
secreted factors on cancer cell invasion through ECM.34 Following adhesion of tumor cells
to peritoneal mesothelium, rapid mesothelial cell retraction is initiated, resulting in exposure
of the interstitial collagen-rich sub-mesothelial matrix to which OvCa cells avidly adhere via
integrin-mediated interactions [Figure 1A]. 33,35,36 The resulting integrin engagement and
clustering modify gene expression profiles, altering the expression of genes that potentiate
matrix penetration, anchoring, and proliferation.2,18
2.4 Complex three-dimensional organotypic models with multiple cell types and
extracellular matrices
A recent model of OvCa metastasis provides an environment that more closely mimics the
in vivo human peritoneal microenvironment, as it includes the superficial layer of the
peritoneum (“mesothelium”) to include both mesothelial cells and the sub-mesothelial ECM
interspersed with primary human peritoneal fibroblasts.15 The 3D organotypic model uses
tumor-derived primary human OvCa cells or cancer cell lines cultured with omentum-
derived primary human mesothelial cells, primary human fibroblasts and patient-derived
extracellular matrix [Figure 1C].37 This model recapitulates key events in OvCa metastasis
including adhesion, proliferation, and invasion, thereby re-establishing morphological and
functional features of the corresponding tissue in vivo.37 By using fluorescently labeled cells
and fluorescence-activated cell sorting, changes in gene or protein levels and post-
translational modification can be individually investigated in the cancer cells, mesothelial
cells or fibroblasts after co-culture. Thus far, the 3D “mesothelium-mimetic” organotypic
culture has contributed to our understanding of the role of c-Met38, MMP-239, HOXA940, E-
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cadherin12, β3-integrin41 and α5-integrin12 in early OvCa metastasis. The 3D organotypic
culture of peritoneal metastasis is particularly suited for use as a predictive preclinical model
for drug testing, since drug sensitivity in ex vivo and in vivo studies can be recapitulated in
the 3D model.38,39 Furthermore, this model can be expanded to use other cell types (e.g.
adipocytes42, macrophages) and provides a system to test the effects of treatments on both
normal peritoneal cells and tumor cells, and may be modified for use in high-throughput
screening (HAK, EL unpublished).
2.5 Peritoneal and organ explants
Three dimensional systems using ex vivo human or mouse peritoneal or omental explants are
used to evaluate OvCa tumor cell interactions with intact peritoneal tissue (MSS,
unpublished).39,43 Dissected peritoneal explants can be pinned to optically clear silastic
resin and incubated with OvCa cells or multi-cellular aggregates [Figure 1D]. Use of
fluorescently-tagged OvCa cells enables optical monitoring of adherent cells as well as
visualization by confocal microscopy. Scanning electron microscopy can also be used to
visualize the morphology of early heterogeneous cell-cell adhesive interactions.
Furthermore, explants can be histologically sectioned and used to quantify depth of tumor
cell penetration under various conditions. This model confers the ability to monitor the
extent and kinetics of adhesion, observe early events in peritoneal anchoring, and test
potential anti-adhesive therapeutics. Similarly, tissue explants can also be used to evaluate
pre-neoplastic changes in potential progenitors from the ovary and fallopian tube. For
example 3D alginate scaffolds have been used to support the ex vivo growth of ovarian
surface cells, normal mouse oviducts and baboon fimbria.44–46
In the current iteration, these models are limited by the lack of vasculature, immune and
endothelial cells, and other extracellular components present in vivo as well as by the ability
to provide reproducible conditions only for a short period of time (<1 week). Nevertheless,
the development and use of advanced 3D and ex vivo OvCa models can bridge the gap
between in vitro studies, OvCa mouse models, and the in vivo human disease. The choice of
a model system for a given experiment should reflect the experimental question to be
addressed and the stage of OvCa metastasis under investigation.
3 CELL LINES AND XENOGRAFTS
Although OvCa cell lines and primary tissues that recapitulate the molecular diversity,
cellular heterogeneity, and histology seen in patient tumors are available, there is no uniform
collection or structured overview of these valuable reagents. Here we summarize the most
frequently used OvCa cell lines, including those used as xenografts (Supplementary Table
S1). The positive attributes of cell culture include ease of propagation, relatively low cost,
ability to control culture conditions, less heterogeneous cell populations, and the presence of
side population cells which represent a renewable source of OvCa stem cells. Cell culture is
limited, however, by the absence of the tumor microenvironment, artifacts from prolonged
culture conditions in unphysiological culture medium on plastic, high passage number, and
the lack of patient-matched normal cell counterparts. When these cells are used to generate
xenografts, positive attributes include recapitulation of tumor heterogeneity with recruitment
of host stromal cells and maintenance of both tumor stroma and tumor/non-tumor
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vasculature interactions. This is balanced by the time and expense of these models and the
maintenance of only a small portion of niche cells which do not represent the entire tumor.
3.1 Serous ovarian cancer epithelial cell lines and intraperitoneally derived xenografts
Most high-grade serous OvCa cell lines (Supplementary Table S1) have been derived from
ascites of patients ranging from chemotherapy naïve to heavily treated, with various stage
malignancies47. Cell lines established from patient whole tumor tissue (rather than ascites),
that are considered platinum-sensitive, include HEY48, derived from the peritoneal deposit
of a moderately differentiated papillary cystadenocarcinoma49, and the cisplatin-resistant
derivations HeyA8 and HeyC2, both generated by passaging HEY in athymic nude mice.48
OVCAR-450 was developed from a patient refractory to platinum-based chemotherapy, and
Caov-351 from the solid components of a serous OvCa prior to treatment with
cyclophosphamide, adriamycin, and 5-fluorouracil. Given that taxanes are the second
cornerstone of OvCa treatment, a paclitaxel-resistant subline (SKOV3TR) was derived from
SKOV-3 cells through selection in incrementally increasing paclitaxel concentrations.52,53
Some cell lines have been treated with chemotherapeutic agents to produce resistant sub-
lines.54 Drug resistant sub-lines of A2780, which are all cisplatin resistant at the
corresponding micro molar values, include CP70, C30, and C200. An adriamycin-resistant
A2780 cell line, A2780ADR (100nM resistance and cross-resistant to melphalan and
vinblastine)55 and paclitaxel-resistant A2780 sub-lines, PTX10 and PTX22 (5ng/mL and
15ng/mL, respectively)56, are also available. The IGROV-1 cell line was derived from the
ovarian tumor of a patient with stage III human ovarian adenocarcinoma who had not
received chemotherapy. By subjecting the chemotherapy-naïve cells to 0.5μg/mL and
1.0μg/mL cisplatin, IGROV-1/Pt 0.5 and IGROV-1/Pt 1 sub-lines were developed. The
chemo-resistant 2008 cell line was established from a serous cystadenocarcinoma of the
ovary. Monthly treatment of 2008 with 1μM cisplatin with subsequent selection resulted in
the 2008 *C13 subline57. Deep sequencing data for IGROV-1 cells are available58 and the
line is also included in the NCI 60 cell line panel. Indeed, 6 OvCa cell lines (OVCAR-3,
OVCAR-4, OVCAR-5, OVCAR8, IGROV-1, SKOV3) are included in the NCI 60 cell lines
and are used by the NCI for in vitro drug screening. Therefore, they can be considered as the
most extensively characterized set of OvCa cell lines, with drug sensitivity, microRNA,
mRNA and proteomic profiling data available.59 Most importantly, their genetic identity can
be verified through DNA fingerprinting60, allowing reliable confirmation of their identity.
A number of the cell lines are suitable for development as murine xenografts
(Supplementary Table S1, Figure 2A–B). OVCAR-3 has been successfully passaged in mice
and developed as an i.p. xenograft that retains many characteristics of its human tumor
counterpart with histology similar to a serous OvCa.61 SKOV362 and PEO2363 were
collected on relapse after cisplatin and chlorambucil treatment and represent well
differentiated serous adenocarcinoma cell lines that form xenograft tumors with a histology
that is also very similar to a human serous cancer. Passaging the SKOV3 cells in nude mice
allowed the development of several sublines (SKOV3ip.164, SKOV3x65) that grow as
disseminated disease in the abdomens of nude mice. This mouse model is characterized by
numerous (100–200) small nodules on the surface of the peritoneum, bowel mesentery, and
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diaphragm and the transformation of the mouse omentum into a larger tumor39,64,65,
mimicking human advanced stage serous-papillary OvCa [Figure 2A]. When gene
expression in SKOV3 was compared to that of SKOV3ip.1, the latter showed upregulation
of v-erb-b2, FGFR1, MMP-19 and downregulation of nm23B66, possibly explaining the
rapid growth of these cells as xenografts. OVCAR-367 and OVCAR-5 [Figure 2Ba] have a
similar widely disseminated xenograft growth pattern. In contrast, intraperitoneal injection
of HeyA8 cells yields a few large tumors that grow in the ovaries and mouse omentum
without peritoneal dissemination [Figure 2Bb], mimicking a distinct human OvCa growth
pattern.68 Most OvCa cell lines can be successfully transfected or transduced to express
fluorescent or bioluminescent vectors to enable longitudinal optical imaging of tumor
growth [Figure 2Ab-c, 2Bc]. Furthermore, the i.p. and s.c. take rate of human OvCa cell
lines can be improved by mixing them before injection with Matrigel.16
3.2 Clear cell, endometrioid, and mucinous ovarian cancer cell lines
Clear cell carcinoma, which is by definition a poorly differentiated high grade tumor, is
represented by several OvCa cell lines [Supplementary Table S1], including ES-269,
TOV-21G70, OVISE and OVTOKO71, and TYK-nu and OVMANA.72 ES-2 cells exhibit
low to moderate resistance to a number of chemotherapeutic agents including doxorubicin,
cisplatin, and etoposide. OVISE and OVTOKO were established from metastatic tumors of
two patients after treatment with five to six courses of chemotherapy. Both lines are
insensitive to cisplatin, doxorubicin, cyclophosphamide, and etoposide. Interestingly, i.p.
injection of the OVTOKO cells yields peritoneal implantation and distant metastasis in a
mouse model, whereas OVISE cells showed no dissemination and metastasis. OVISE
contains a homozygous ARID1A mutation often observed in human clear cell cancers.6
Both TYK-nu and OVMANA have been fully sequenced and a PIK3CA mutation in
OVMANA was identified72 that recapitulates the genetic changes observed in human clear
cell OvCa.5
Endometrioid OvCa is represented by several cell lines [Supplementary Table S1]. The first
endometrioid cell line was MDAH2774, developed from cells in the ascitic fluid from a
patient with endometrioid OvCa and forms tumors in nude mice.73 59M was established
from the ascitic fluid sample of patient who previously presented with a synchronous stage
IA carcinoma of the ovary and an in situ carcinoma of the endometrium.74 COV362 was
established from a pleural effusion, and like its sub-clone COV362.4, shows anchorage-
independent growth in agar.75 TOV-112D was derived from a Grade 3, stage FIGO IIIC
endometrioid OvCa.70 A mouse endometrioid cancer cell line76 has been established from
the LSL-KRasG12D;Ptenfl/fl mouse model.77 EFO-27, representing a mucinous papillary
adenocarcinoma, was derived from a solid omental metastasis.47
3.3 Primary ovarian and fallopian tube cells, immortalized lines, and establishing lines
from primary ovarian tumors
Establishing primary OvCa cells has remained a challenge as the optimal cell culture
medium and ECM to successfully and reproducibly culture primary OvCa has remained
elusive even though various methods have been published. During the initial process of
establishing a cell line from a patient tumor rapidly growing contaminating cells, such as
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fibroblastic and stromal cells, can out-compete the cancer cells in culture. Precautions to
avoid non-cancer cell contamination include Percoll gradient separation and isolation with
CD45 antibodies.78,79 Other methods to isolate primary OvCa cells from ascites and solid
tumor tissue include enriching tumor cells using immunomagnetic beads coupled to EpCAM
antibodies80 or filtration through a nylon cell strainer81 and the use of optimized media
previously shown to enhance the growth of breast cancer cells.82 The primary cells may be
characterized by EpCAM and HE4 protein expression and CK7 mRNA expression.81
Since the OvCa cell of origin may be the abdominal peritoneum, the surface epithelium of
the ovary7 or the fimbriated end of the fallopian tube83, culturing the primary epithelial cells
from these sites is crucial to identifying the pathways involved in the neoplastic
transformation of serous OvCa. However, when attempting to propagate these primary
epithelia in vitro, culture conditions induce senescence and differentiation. Propagation of
human immortalized ovarian surface cells (IOSE)84 and fallopian tube fimbria has been
made possible by stable transfection with SV40 T antigen.85,86 For example, IOSE-29 does
not form tumors, while its neoplastic counterpart IOSE29EC forms s.c. and i.p. tumors in
SCID mice.87 Immortalized fallopian tube cell lines used for i.p. injection retain gross,
histological, immunophenotypical and genomic characteristics similar to human high grade
OvCa.8,88 When fimbrial cells are cultured on collagen-coated transwells, cell polarization is
enhanced, which allows the investigation of DNA damage from chemotherapy and other
sources.88 The use of a 3D alginate scaffold also supports the growth of normal mouse
oviducts and ovarian surface cells, as well as baboon fimbria.44–46 A human fallopian tube
cell line has also been established from tumor tissue.89
3.4 Mouse and rat ovarian cancer cell lines
The syngeneic mouse model allows OvCa initiation directly from mouse OSE (MOSE).
MOSE are scraped from the mouse bursa and are passaged in culture on plastic until
phenotypic changes occur, such as the loss of cell contact inhibition, which results in
cellular mounds and changes in cell morphology.90 During neoplastic progression in the cell
culture dish, the tumor-suppressor proteins E-cadherin and connexin-43 are lost,
distinguishing early from late MOSE.91 When MOSE are injected i.p. into C57BL6 mice,
ascites and metastatic tumors form by about 90 days92, while s.c. injected cells cause solid
tumor formation confined to the injection area. When non-transformed cells are injected i.p.
and s.c., no tumor formation is observed. The most commonly used mouse OvCa cell line is
ID8, developed in vitro from ovaries of the C57BL6 mouse strain.90 The MOSE cells IG10
and IF5 are cognate tumor-inducing clonal cell lines which in vivo have very different
survival times and tumor loads (IF5: 182 ±3 days, IG10 72±2 days).
Although the transformation into MOSE occurs in vitro, the MOSE system may to some
extent recapitulate progression of normal OSE to an epithelial OvCa. A rat ovarian
orthotopic xenograft variant has been reported that uses the spontaneously immortalized rat
surface ovarian epithelial cell line NuTu-19 in Fisher 344 immunocompetent rat hosts. In
this model, development of pelvic extension and peritoneal metastases were dependent upon
the number of injected cells.93 The syngeneic mouse or rat orthotopic models are very useful
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for studies requiring the preservation of an intact immune system and can be used to confirm
results obtained with xenograft models.
3.5 Cell line authentication
Good cell culture practices and the observation, monitoring, and documentation of cell
morphology, behavior, and growth rates will reduce the frequency of cell misidentification.
Changes may indicate microbial contamination, genotypic drift due to high passage number,
or cross-contamination with another cell line. Given these daily risks and the tremendous
implications of using the wrong cell line for experiments, the authentication of cell lines is
now being emphasized by scientific journals and granting agencies. Human cell lines should
be regularly authenticated and identified using DNA short-tandem repeat (STR) profiling.94
Although OvCa cell lines derived from a multitude of sub-types are available, and multiple
OvCa cell lines have been assessed in a single study, availability of a collection of regularly
authenticated, mycoplasma tested, and well characterized epithelial OvCa cell lines would
be optimal, a need in the field highlighted by a recent report on the extent of OvCa cell line
misidentification 95. Ideally, the cell lines would be accompanied by extensive genetic/
epigenetic and other molecular information.
3.6 Ovarian cancer stem cells
Ovarian cancer stem cells have now been isolated from a number of sources, including
primary tumors, ascites, and established OvCa cell lines.53,96–99 The first report of the
isolation and identification of stem cells from OvCa patients described two ascites-derived
clones able to form multicellular-aggregate, anchorage-independent spheres in culture, and
serially propagate xenograft tumors in nude mice that were histopathologically similar to
their parental tumors.96 A number of surface markers have been used to isolate stem cells
from primary patient OvCa (Supplementary Table S2). In addition, subpopulations of
tumorigenic stem-like “side populations” cells in cultures of OVCAR3, IGROV-1, and SK-
OV-3 have been reported.98,100 Since these represent a small population of chemoresistant
cells in a tumor, the development of model systems that include stem cells may lead to a
better understanding of tumorigenesis and drug resistance in OvCa.
3.7 Orthotopic implantation of cell lines and whole tissue tumor grafts (“Xenopatients”)
Early events in metastasis cannot be fully appreciated when i.p. xenografts are used, since
they rely on the artificial dispersion of single cell suspensions of cancer cells in the
peritoneal cavity, rather than dissociation of metastatic cells from an intact primary tumor
tissue. Orthotopic ovarian xenografts may mimic more closely the process of dissemination
from the primary ovarian tumor relative to the i.p. xenografts discussed above and are
therefore well suited for studying metastasis. However, there are significant anatomic
differences between rodents, which have a closed bursa at the end of a long and coiled
fallopian tube with longitudinal folds enclosing the ovary101, and humans where the tube is
straight, short, and the epithelium is exposed to the peritoneal cavity. Several approaches
have been utilized for orthotopic mouse models: injection of cancer cell lines under the
ovarian bursa, implantation of human or murine tumor fragments adjacent to the ovary or
under the renal capsule, and i.p. injection of minced human tumor.102–105 Critical steps in
the metastatic process are invasion through the ovarian bursa followed by peritoneal spread
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with colonization and invasion of the organs in the peritoneal cavity. Intrabursal injection of
OvCa cells causes tumor formation in the ovary, but peritoneal dissemination may not occur.
Moreover, only a small volume (>5μl) can be injected under the fat pad without causing
mechanical disruption of the bursa and peritoneal spillage.
Implantation of whole human OvCa tissue fragments under or adjacent to the ovarian bursa
of SCID mice generates ovarian tumors that histologically resemble the tumor of origin.102
In this model, tumor take rate is approximately 65% at 16 weeks and production of
malignant ascites has been recorded, although metastases occurred infrequently. However,
in one study using initial implantation of intact human ovarian tumor fragments, metastatic
dissemination initiated from orthotopic ovarian tumors was reported following serial
passage of human xenografts in the ovarian fat pad.106 After several passages, peritoneal
spread was recorded, resembling the clinical features of the human disease. Higher tumor
take (~95%) is observed when fragments of human ovarian tumors are implanted under the
renal capsule of SCID mice104, perhaps reflecting a more permissive host milieu facilitated
by the rich kidney vasculature. While tumor growth was generally slow and observed
metastases were rare, the histological and immunophenotypic characteristics of the original
tumor are preserved in the tumor graft. Growth of less aggressive tumors, such as benign,
borderline, and granulosa tumors is also possible when fragments are implanted under the
renal capsule.
An alternative method to implantation of full tissue fragments, which requires mouse
surgery, is to inject a finely minced primary human tumor slurry directly i.p in mice.107
Mice are then monitored for engraftment using manual palpation and small animal
ultrasound. This methodology has led to a high engraftment rate (~74%) from over 200
consecutive patients with untreated ovarian, primary peritoneal and fallopian tube
cancers.105 The “xenopatients” recapitulated the histological [Figure 2C], molecular and
platinum-sensitivity characteristics of the source patient tumors. Thus, “xenopatients” could
be useful models for assessing response to therapeutic interventions or biomarker discovery
in a manner reflecting the behavior of the original tumor. Indeed, response to platinum
chemotherapy was recorded in an orthotopic serous fallopian tube explant, mirroring the
clinical response of the donor patient.108 These data suggest that these models, albeit very
labor-intensive, may be useful tools for individualizing patient therapy.
4 GENETICALLY ENGINEERED MOUSE MODELS OF OVARIAN CANCER
Genetically engineered mouse models (GEMMs) of OvCa, which can closely recapitulate
human disease, have the potential to greatly improve our understanding of OvCa biology.109
These models, involving genes expressed or deleted specifically in the ovary or the fallopian
tube, allow us to evaluate the physiological relevance of defined genetic changes in OvCa
and to better understand the mechanistic significance of genetic lesions revealed in human
tumors. Such pre-clinical models are clearly also suited for testing new compounds for
cancer prevention76 and therapy110,111, since they can be used to model drug resistance as
well as contribute to the discovery and validation of novel serum biomarkers. GEMMs of
OvCa are summarized in Supplementary Table S3.
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4.1 GEMM using various combinations of p53, RB, Myc, Akt and Pten
Generating GEMMs of OvCa in which the fallopian tube or ovarian surface epithelium
(OSE) is specifically targeted has proven difficult due to the lack of defined transcriptional
promoters active specifically in these cell types. One of the first animal models of OvCa
used the TVA receptor system driven by the epithelial specific cytokeratin 5 (CK5)
promoter to delete the p53 tumor suppressor in isolated ovarian surface epithelia in vitro.112
OSE cells in which p53 had been deleted in this manner were then infected in vitro with
retroviruses expressing combinations of relevant oncogenes (c-myc, K-ras, and/or Akt). The
cells, now with altered gene expression, were transplanted into host mice. This process
ensured that tumors were unlikely to arise from tissues other than OSE that express CK5.
These mice developed OvCa with papillary structures consistent with serous OvCa and
using these mice it was shown that rapamycin inhibits the growth of tumors depending on
Akt activity.110 Subsequent work showed that a single oncogene, in this case c-Myc, was
sufficient to drive OSE tumorigenesis when both p53 and BRCA1 were deleted using the
TVA system.113 Clearly, this model showed that the ovarian surface is capable of forming
tumors when the correct oncogene and tumor suppressor gene mutations are introduced.
The lack of defined cell type specific promoters continues to hinder more conventional
transgenic approaches to driving the deletion or activation of relevant tumor suppressors and
oncogenes in the OSE. Since the promoters used to express genes in OSE are also active in
other tissues of Müllerian origin (fallopian tube, uterus, cervix, ovarian granulosa cells), the
origin of emerging “ovarian” tumors in the mouse model is open to question. One of the
most effective promoters used to drive Cre recombinase or other transgenes has been the
promoter of the Müllerian Inhibiting Substance II Receptor (MISRII) gene, also known as
the Anti-Müllerian Hormone Type II Receptor (AMHRII). The MISRII promoter primarily
drives transgene expression in the ovarian surface and ovarian granulosa cells, but it also
expressed the transgene in the mesenchyme of the oviduct. The first transgenic mouse model
to utilize the MISRII promoter used it to drive expression of the SV40 large T antigen
(SV40-Tag), a viral oncogene that binds to and inactivates both p53 and all members of the
retinoblastoma (Rb) pocket protein family of cell cycle regulators. As a result,
approximately 50% of the animals developed large undifferentiated ovarian
adenocarcinomas by 90–100 days.114 In order to more effectively control the timing of
oncogene expression, a Lox-STOP-Lox (LSL) cassette was inserted between the SV40-Tag
and the ubiquitous CAG promoter. Oncogene expression was then induced following direct
intrabursal injection of adenovirus expressing Cre-recombinase, which, theoretically, only
reached oviductal and ovarian surface epithelial cells.115 Approximately 89% of the pCAG-
LSL-SV40-Tag mice injected in this way developed poorly differentiated tumors with
metastasis throughout the abdominal cavity, similar to the tumor type and incidence
observed when SV40-Tag expression was driven by the MISRII promoter.114,115 Thus,
intrabursal injection and MISRII both effectively target the ovarian surface, while SV40-Tag
expression in the oviductal mesenchyme does not induce oviductal tumors.
Cre-Lox technology has been used more extensively to induce targeted deletion of the Pten
tumor suppressor and to activate the K-Ras oncogene. In two separate models, LSL-
KRasG12D;Ptenfl/fl mice were induced to develop ovarian tumors either through adenoviral
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delivery of Cre77 or through expression of a Cre transgene under the control of the
aforementioned MISRII promoter.116 The MISRII-Cre; LSL-KRasG12D; Ptenfl/fl mice
develop a form of low grade epithelial serous cancer derived from the ovarian surface with
100% penetrance. This is currently the only transgenic mouse that models a low grade
serous OvCa.116 In contrast, when tumors were induced in LSL-KRasG12D;Ptenfl/fl mice by
infection of the OSE with adenovirus expressing Cre-recombinase, the mice developed
endometrioid or poorly differentiated carcinomas [Figure 2D].77 In this model, adenoviral
vectors that express Cre recombinase were used to selectively express or delete genes in the
ovary. These vectors are injected into the ovarian bursa, theoretically only reaching
oviductal, ovarian surface epithelial, and bursa cells. However, in practice they sometimes
leak out through the injection site and reach uterine tissue. The difference between these two
models, both of which target K-Ras and Pten, is the manner in which Cre is delivered. 77,116
This illustrates the importance of defining the target tissue and developmental timing for
deletion/activation of the critical oncogenes and tumor suppressors. For example, follicular
depletion and a loss of circulating ovarian hormones such as estrogen are evident in the
MISRII-Cre; LSL-KRasG12D;Ptenfl/fl mice116 but not in the Ad-Cre; LSL-KRasG12D;Ptenfl/fl
mice.117 To what extent such developmental and follicular effects of transgene expression
play a role in tumorigenesis in these mice is not clear.
The Pten tumor suppressor has also been deleted in mice in combination with the Apc tumor
suppressor, a signaling molecule in the Wnt/β-catenin pathway.118 The combined deletion of
Pten and Apc by intrabursal injection of Cre-recombinase expressing adenovirus resulted in
the formation of the endometrioid sub-type OvCa in all injected animals118, similar to that
seen in the Ad-Cre; LSL-KRasG12D;Ptenfl/fl mice.77 These animals develop a more
aggressive phenotype when additional mutations in p53 and in PI3Kca are introduced.119
Based on the observation that the AKT pathway is up-regulated in human OvCa due to the
mutation or amplification of the PIK3CA gene5, a mouse model has also been designed with
an activating mutation in PI3K (PIK3CAH1047R) that, when combined with deletion of Pten,
led to robust activation of the Akt pathway. After intrabursal adenoviral Cre-recombinase
injections, the Ad-Cre; PIK3CAH1047R;Ptenfl/fl mice formed ovarian serous
adenocarcinomas or granulosa cell tumors.111 This model has been used to test the efficacy
of a PI3K/mTOR pathway inhibitor which was initially effective in inhibiting tumor growth,
although the tumors eventually became resistant.111 These distinct mouse models of OvCa
in which Pten is deleted demonstrate that Pten deletion alone is not sufficient for tumor
formation, but the specific context of Pten deletion in the OSE or in the OSE and granulosa
cells impacts the histotype and grade of the cancer formed.
4.2 GEMM of BRCA mutations
The BRCA1 and 2 genes are either mutated or silenced by methylation in approximately
20% of all high grade OvCa.4 Several conditional BRCA1 and BRCA2 mouse models have
been generated. In these, the BRCA allele, flanked by LoxP sites, is deleted either by Cre-
recombinase expression driven by the MISRII or FSHR promoter, or by adenoviral
injection.117,120–122 Targeted deletion of only BRCA1 or BRCA2 in the ovaries is generally
not sufficient to induce malignancy, although FSHR promoter driven deletion of only
BRCA1 did generate cystic tumors in one model.117 The prolonged estrous phase and
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enhanced estrogen signaling in this model may account for this phenotype, since FSHR is
expressed in granulosa, ovarian surface, and oviductal cells.117 Tumor formation may be
influenced either by loss of BRCA1 in cells other than those of the ovarian surface or oviduct
or by the effects of increased estrogen signaling in cells without BRCA1. Conditional loss of
BRCA1 alone (Cre-recombinase injection into the bursa) was insufficient to generate tumors
and resulted in hyperplasia of the OSE. Combining loss of BRCA1 with loss of p53 resulted
in either leiomyosarcomas or no tumors at all, unless the Rb family was also inactivated.120
Loss of BRCA1 in combination with p53 (BRCA1LoxP/LoxP p53LoxP/LoxP) led to
development of a leiomyosarcoma but not a serous OvCa.120–122 In a recently reported
mouse model122 the key event initiating OvCa was the inactivation of the Rb tumor
suppressor and related p107/p130 pocket proteins through targeted expression of a mutant
form of the SV40-Tag that cannot inactivate p53. This, when combined with the inactivation
of p53 and BRCA1 deletion, caused progression to advanced serous OvCa. Similarly,
combined loss of p53 and Rb function led to tumor formation.123
4.3 GEMM of fallopian tube cancer
Since the emergence of the hypothesis that the fallopian tubes may be the primary site of
origin of high grade serous carcinoma124, a few models have been introduced to help
explain potential genetic causes of tubal cancers109. When the oviductal glycoprotein
(OVGP) gene promoter was used to drive SV40-Tag expression, mice developed oviductal,
uterine and vaginal tumors.125 Tumor cells were occasionally found in the ovaries, but it
was not determined if these represented the primary lesion or a metastasis. Recently,
MISRII-Cre; Ptenfl/fl;Dicerfl/fl mice have been generated in which both the Pten and the
Dicer gene, required for efficient micro-RNA processing, were deleted in all tissues of
Müllerian duct origin. These mice developed tumors resembling high-grade serous OvCa in
the mesenchyme of the oviduct that metastasized to the peritoneum, the diaphragm, and
formed ascites.126 Histologic analysis and gene expression profiling suggested that these
tumors resembled high-grade serous cancer in humans; however, the tumors did not have
mutations in BRCA, p53 or deficiencies in homologous repair.126 This GEMM consistently
develops high-grade serous cancer, which metastasizes within the abdominal cavity in a very
similar fashion to human OvCa. Interestingly, a recent abstract suggests that a Ptenfl/fl;
Dicerfl/fl/p53LSLR172H/+ triple knock out develops both tubal and ovarian tumors.127 Thus,
it remains to be determined whether the epithelial expression of the “p53 signature” in
BRCA-mutant human OvCa and the formation of serous cancers from the stroma in this
mouse model126 can be reconciled in terms of human disease origin. Lastly, very recent
reports suggest that an inducible Pax8-TetON system can generate a high grade serous cancer
from the fallopian tube epithelium when p53 and BRCA1 or BRCA2 are simultaneously
deleted.128 The tumors were more likely to be found in the proximal rather than the distal
portion of the oviduct. It is the distal portion that is anatomically comparable to the fimbriae
of the human fallopian tube and is the more likely site of OvCa formation. This discrepancy
in tumor localization when compared to human disease may be explained by the relative
strength of the Pax8 promoter in transgenic mice.
GEMMs offer the potential to introduce specific modifications to pathways in a time and
tissue dependent manner that can help to confirm or deny the importance of genetic
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mutations in disease onset and chemoresistance. Other advantages of GEMMs are that OvCa
develop disease in a shorter time period than non-human primates and chickens allowing
studies to be completed quickly. With the use of viral delivery to introduce cre-recombinase,
mutations can be turned on and off in different stages of tissue development. Criticism of
GEMMs were raised due to concerns that the existing GEMMs do not employ genetic
lesions relevant to human high grade serous cancers and, in many instances, may be driven
by inappropriate regulatory sequences and promoters, which may explain, in part, their
failure to recapitulate the peritoneal dissemination clinically observed in human OvCa.
Unfortunately, OSE do not express a tissue specific promoter and a promoter only expressed
in specific epithelial cells of the fallopian tube (e.g. secretory cells8) has not yet been
uncovered. Another drawback of GEMMs is that they can produce different phenotypes due
to the background strain of the mouse model.120,123 Since human OvCa is genetically
complex, it is likely that genetic mouse models represent only one particular molecular
subtype of OvCa, rather than the entire spectrum of the corresponding human disease.4
5 THE LAYING HEN MODEL OF EPITHELIAL OVARIAN CANCER
One of the major obstacles to progress in OvCa prevention and treatment is a dearth of
spontaneous disease models. The primary animal model available for the study of
spontaneous epithelial OvCa is the laying hen.129 As early as the 1960s, reports identified
domestic egg-laying hens as probable surrogates for human OvCa and suggested that they be
investigated as potential models.130,131 A landmark large scale epidemiological study
documented an age dependent onset of the disease, with the first occurrence of OvCa
observed in hens of 2–2.5 years of age with an incidence of 4%, while in hens aged from 4–
6 years the incidence was 30–50%.132 These findings have been confirmed in a recent study
demonstrating that the first observable incidence of spontaneous OvCa was in hens aged
between 2–2.5 years with an incidence of epithelial OvCa of all stages that reached a peak of
nearly 60% at 4 years.133 A distinct advantage of pre-clinical studies in laying hens is that
large-scale studies with hundreds of animals, conducted over extended periods of time, can
be performed at relatively little cost. After a hen has completed her 2nd year of laying,
producing from 300 to 500 eggs, she has ovulated approximately the same number of times
as a woman who has undergone menopause, when the risk of OvCa increases
dramatically.134 A considerable body of epidemiological data supports the link between the
number of lifetime ovulations and OvCa risk. Specifically studies using the domestic hen,
support the “incessant ovulation” hypothesis by showing that when ovulation is arrested in
hens, either (i) pharmacologically by dosing with progestins135, (ii) using a model of
restricted ovulation through nutrient deprivation, or (iii) via genetic selection for low-egg
laying variants the incidence of OvCa is lower.135–137 The high rate of OvCa in egg-laying
hens could be the consequence of genomic damage to the ovarian surface epithelium
associated with incessant ovulations or may indirectly result from facilitated genetic changes
or impaired DNA repair which ultimately lead to the development of OvCa in the hen. A
direct relationship between ovulation and OvCa remains to be determined.129
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5.1 Description of the hen model
Epithelial OvCa in the hen presents with many features of the human disease [Figure 3A, B]
including heterogeneity with at least four clearly distinguishable histological subtypes. In
contrast to human OvCa, in which serous disease represents 70% of late stage disease, 50%
of late stage tumors in the hen have histologic features of endometrioid carcinoma in the
primary tumor and corresponding peritoneal metastases.138,139 However, similar to their
human counterparts, hens exhibit clear cell, endometrioid, mucinous and serous histological
subtypes [Figure 3C]. The clinical presentation in hens is similar to that in women, in that
hens develop substantial volumes of ascites fluid, peritoneal dissemination of metastases,
and pulmonary emboli. Hens develop solid tumors in the lung parenchyma, which is rare in
women with advanced serous OvCa, but may be observed in human endometrioid or clear
cell cancers.140
Certain molecular markers of human OvCa are reproduced in the hen including early
expression of E-cadherin [Figure 3D]139, up-regulation of COX-1141, alterations in p53, K-
Ras and Her2/neu142; expression of CA125143, and several surrogate immunohistochemical
markers, including PCNA, p27, TGFβ1, cytokeratin AE1/AE3, pan cytokeratin, EGFR,
Lewis Y, CEA, Tag 72, and erbB-2.144 Gene profiling studies and bioinformatics
comparisons between laying hen and human cancer gene expression patterns have further
demonstrated the conservation of genetic lesions associated with OvCa and histotype-
specific mutations.142,145,146 Because of the importance of the chicken as a meat-animal and
its extensive use as a model for developmental studies, robust genomic resources for the
chicken have been developed, including cDNA, long-oligo and GeneChip™ genome
arrays.147,148 The chicken epi-genome has also been mapped.149 Extensive chicken genomic
resources are available via the NCBI150, the Genome Institute at Washington University,
and in a recently published collection of chicken genomic resources.151
5.2 Prevention
The first pre-clinical intervention study in the laying hen evaluated the efficacy of
medroxyprogesterone acetate (Depo-Provera®) in reducing the frequency of spontaneously
developing reproductive tract adenocarcinoma, showing a 15% risk reduction in animals
treated with the progestin.135 The authors observed that the high rate of reproductive tract
adenocarcinoma further supported the use of the laying hen model of spontaneous ovarian
carcinogenesis to test chemoprevention strategies. A recent chemoprevention trial in hens
studied treatment with progestin alone, estrogen alone and progestin plus estrogen.152
Results show that treatment with progestin alone and in combination with estrogen
decreased the prevalence of OvCa with a concomitant reduction in egg laying.135,152 Both
groups concluded that their findings were consistent with the theory that a reduction of
ovulatory events may prevent the development of ovarian adenocarcinoma.135,152 The utility
of the hen model for pre-clinical evaluation of therapeutic modalities for the prevention of
OvCa (reviewed by Rodriguez153) has been demonstrated in studies testing the efficacy of
progestins135,152, anti-inflammatory NSAIDs154; and dietary intervention with flaxseed.155
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5.3 Studies of early ovarian cancer in hens
A distinct advantage of the hen model of OvCa is that the disease arises spontaneously in
chickens and therefore presents investigators with the opportunity to study the initial events
leading to OvCa, identify targets for prevention, and devise and test interventions. One
example of an early event in OvCa development that has been observed in hens and
corroborated in human clinical specimens is the presence of anti-ovarian auto antibodies in
the serum of hens with early stage OvCa.156,157 Another example is the increased
expression of E-cadherin in hen OvCa, which is clearly seen at the point of neoplastic
transformation where normal surface epithelium transitions morphologically into precursor
lesions which develop into early primary tumor sites (as shown in Figure 3Da,c).139 Similar
patterns of increased E-cadherin in inclusion cysts of human ovarian tumors have been
described.7 In addition, the pattern of expression of tubal genes in primary ovarian tumors of
the hen 158 and repetition of the “p53-signature” in pre-neoplastic lesions of the tubal and
ovarian surface epithelium of the hen 141 are conserved in the hen analogous to humans.
5.4 Imaging in hens
Doppler ultrasonography has been employed to analyze the kinetics of an ultrasound
contrast agent used to identify and follow ovarian tumor-associated neo-angiogenesis in
early-stage OvCa in the hen. Findings were corroborated on necropsy.155,159 The kinetics of
the ultrasound contrast agent was shown to be indicative of ovarian tumor-associated neo-
angiogenesis in early stage OvCa. The use of contrast-enhanced ultrasound for the detection
of early ovarian tumors demonstrates the potential for the development of new clinical
diagnostics tools using the hen model. Moreover, the hen model may also be useful for
testing the efficacy of different contrast agents in a preclinical setting.
5.5 Limitations and challenges
There has been very slow progress in the development of stable cell lines derived from
chicken OvCa or ascites for mechanistic studies in hens. Ovarian surface epithelial cells,
tumor cells from primary cancer, and tumor cells isolated from ascites fluid from hens have
been described, but as yet these studies have been limited to primary cultures or cell cultures
with low passage numbers.160 Similarly, there has been very little progress in the
development of transgenic chicken models for the manipulation of targeted genes by over-
expression, mutation, ablation, and silencing. Promising studies, however, have shown that
chick embryos can be genetically manipulated, offering hope for the eventual development
of transgenic chicken models of OvCa.161,162
Another challenge of working with hens is the limited availability of chicken specific
reagents, such as antibodies for immunohistochemical analyses. A panel of commercially
available surrogate cancer antigen antibodies has been examined for their cross-reactivity in
hens144 and successfully adapted for the use with hen tumor tissue using robust antigen-
retrieval procedures. However, despite the clearly demonstrated power of the hen model and
its potential for evaluating therapeutics and preventatives, only a handful of investigators
have taken advantage of the model. Access to experimental poultry facilities and lack of
capacity for chickens in standard biomedical vivarium facilities limit more widespread
adoption of the hen as the standard animal model for OvCa research.
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6 SUMMARY
Within the last five years, significant advancement has been made in developing a more
comprehensive suite of tools with which to experimentally address the pathobiologic
mechanisms that underlie the poor survival of OvCa patients. Despite this progress, the
conduct of experimental translational research in OvCa remains limited by substantial
challenges. For example, a large number of OvCa cell lines have been derived and
maintained in culture, some of which exhibit a chemoresistant phenotype. The value of this
resource would be substantially enhanced by the establishment of a “biobase” collection of
regularly authenticated, well characterized, and well annotated cell lines for distribution to
the research community, similar to the resource available to the breast cancer research
community.163 Access to patient-matched normal and tumor cells, normal epithelial and
mesenchymal cells from other primary sources (for example, fallopian tube), and enhanced
access to well-annotated patient tissue would also facilitate research progress. Several
complex 3D and organotypic models of OvCa metastasis have been developed that take into
account cell and tissue architecture and the contributions of extracellular matrix as well as
stromal and inflammatory cells in the tumor microenvironment. Lacking, however, are
models that contribute to our understanding of the very earliest events in OvCa metastasis;
the shedding of cells from the primary tumor. Use of these models to elucidate molecular
events that initiate and regulate the “terminal transition” from free-floating ascitic cell or
multi-cellular aggregate to peritoneally anchored metastatic lesion may identify novel
therapeutic targets to block metastasis. A challenge will be adaptation of these 3D and
organotypic models to a high throughput format to facilitate drug screening. The use of
murine OvCa models with orthotopic injection into the peritoneal cavity, ovarian bursa, or
kidney capsule has proven utility to address a number of important research questions.
However, evolution in our understanding of OvCa initiation, progression and early stages of
metastasis is hampered by the need for improved genetic models. Identification of more
precise tissue-specific promoters to target genetic lesions (or sets of mutations) identified in
human OvCa tumors to specific tissues in the reproductive tract (ovarian epithelium,
fimbriae of fallopian tube, etc.) would promote progress. In this regard, the laying hen
model of spontaneous OvCa holds promise and the development of additional research tools,
reagents, and approaches for use in this model system is warranted. Lastly, as we realize that
“ovarian cancer” is many diseases, sub-type specific models will need to be developed and
tested. With careful calibration of reagents and experimental models, together with enhanced
collaboration, we are poised for significant advancement of our goal to identify novel,
effective, and personalized approaches to detect and treat ovarian cancer.
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i.p intraperitoneal
LSL Lox-STOP-Lox
MISRII Müllerian Inhibiting Substance II Receptor
MOSE Mouse Ovarian Surface Epithelium
MT1-MMP Membrane Type 1 Matrix Metalloproteinase
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RB Retinoblastoma
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FIGURE 1. Three-dimensional organotypic and ex vivo models of ovarian cancer metastasis
A) Three-dimensional (3D) culture models of cellular contact with sub-mesothelial
collagen. (a) Following initial intra-peritoneal adhesion, mesothelial cell retraction exposes
the sub-mesothelial interstitial collagen-rich matrix to which ovarian cancer (OvCa) cells
avidly adhere. Scanning electron micrograph of murine submesothelial collagen matrix. (b)
Initial multivalent cell-matrix contact of OvCa cell (left) with collagen (right) is visualized
by SEM. (c) Culturing cells atop 3D collagen (as in b) followed by cDNA microarray
analysis can reveal changes in gene expression that result from the initial adhesive contact.
(d) Metastasizing cells migrate into the 3D collagen matrix to anchor metastatic lesions.
Confocal reflectance microscopy overlaid with fluorescence microscopy visualizes cells
within the 3D matrix. (e) Cells seeded into a 3D matrix proliferate in a matrix
metalloproteinase-dependent manner to form expansive matrix-anchored multicellular
aggregates. Micrographs shown in a, b are courtesy of Yueying Liu, University of Notre
Dame and Dr. Katarina Wolf, Radboud University Nijmegen, The Netherlands. Photographs
and micrographs shown in e are courtesy of Dr. Natalie Moss, Northwestern University.
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B) Multicellular aggregate (MCA) cultures mimic non-adherent OvCa cells in ascites.
(a) To generate MCA cultures, cells are suspended at a concentration of 100,000 cells/ml
and seeded as 20 μl droplets on the inner surface of a tissue culture dish lid. After addition of
PBS to the culture dish to maintain humidity, the lid is gently inverted. Following
aggregation, individual MCAs may be subcultured for use in additional assays. (b) Light
micrograph of individual MCA generated using DOV13 cells. (c) Dispersal of MCA
generated from DOV13 cells. An individual MCA was subcultured onto a coverslip coated
with type I collagen and photographed after 12 hours. Dispersal can be quantified by DAPI
staining and measuring inter-nuclear distance.2 (d) Fluorescence micrograph of individual
MCA generated using CellTracker Red-labeled DOV13 cells. (Scale bar 30 μm) (e)
Scanning electron micrograph of MCA generated using DOV13 cells. MCAs were placed in
primary fixative (2% glutaraldehyde, 2% paraformaldehyde in 0.1 M Cacodylate buffer pH
7.35) followed by fixation with osmium tetroxide, dehydration in ethanol, and critical point
drying. Platinum coated samples were examined using a Hitachi S-4700 Field Emission
Scanning Electron Microscope (scale bar 50 μm). (f) Transmission electron micrograph of
MCA generated using DOV13 cells. Following primary fixation as described in e, samples
were encapsulated in HistoGel, fixed with osmium tetroxide, dehydrated in ethanol and
acetone, infiltrated with Epon/Spurr’s resin and cut into ultrathin sections. Sections were
mounted on nickel grids, stained with uranyl acetate and Sato’s Triple Lead stain and
examined using a JEOL 1400 transmission electron microscope (scale bar 10 μm).
Micrographs shown are courtesy of Yuliya Klymenko, University of Notre Dame.
C) Ovarian cancer in vitro models recapitulate peritoneal metastasis. (a) Ovarian cancer
growing as spheroids in a 3D matrix. (b) A 3D peritoneal culture using primary human
peritoneal mesothelial cells and extracellular matrix to investigate OvCa cell adhesion. (c) A
3D organotypic “meso-mimetic” culture of the peritoneal cavity. Primary human omental
fibroblasts are embedded in extracellular matrix and a layer of primary human omental
mesothelial cells plated on top. Ovarian cancer cells are added to the culture and adhesion,
invasion, and proliferation of the cancer cells is investigated. Using fluorescently-labeled
OvCa cells, changes in gene and protein expression can be individually evaluated in the
cancer and stromal cells.
D) Ex vivo peritoneal explant model of early events in intra-peritoneal adhesion. (a)
Optically clear silastic resin is generated using a Sylgard® 184 silicone elastomer kit
(Fisher), using approximately 6 ml per well of a 6-well culture plate. Dissected murine
peritoneal tissue obtained from a midline incision is pinned mesothelial-side up to the
silastic resin and immersed in PBS. Tissue integrity is maintained for up to 48 h. Addition of
fluorescently tagged tumor cells to the explant enables monitoring by (b) relative
fluorescence of cell lysate, (c) fluorescence microscopy of frozen sections, (d) confocal
microscopy, or (e) scanning electron microscopy. Beneath the tumor cells in (e, round), the
cobblestone mesothelium is visible. Note that images in panels (b–d) are representative of a
2 h time point following addition of OvCa cells to the explant. Photographs and micrographs
shown are courtesy of Yueying Liu, University of Notre Dame.
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FIGURE 2. Cell line-based and patient-derived in vivo xenograft models
A) Optical imaging of disseminated i.p. metastasis. (a) SKOV3ip.1 cells were transduced
using a lentiviral vector to express red fluorescent protein (RFP), followed by i.p. injection
(5×106 cells) into nude mice. After 24 days, mice were sacrificed, the peritoneal cavity
opened and metastatic nodules visually enumerated. (b) Fluorescent images of peritoneal
organs in situ were taken using a Xenogen IVIS Lumina imaging system. (c) Dissected
organs were imaged using a Xenogen IVIS Lumina system. Yellow arrow indicates
dissected omentum. Photographs shown are courtesy of Yueying Liu, University of Notre
Dame.
B) Distinct in vivo growth patterns of ovarian cancer cells mimic human metastatic
dissemination. (a) OVCAR-5 cells (1×106) were injected i.p. into nude mice. After 45 days,
mice were sacrificed. Blue lines outline widely disseminated growth of the xenograft as
small peritoneal nodules. (b) HeyA8 cells (1×106) were injected i.p. into nude mice. After
28 days, mice were sacrificed. Blue lines outline the growth of large tumors. (c) HeyA8 cells
(0.5×105) expressing luciferase were injected s.c. into the mouse flank in the absence (blue
circle) or presence (red circle) of carcinoma-associated fibroblasts (CAFs, 1×105). After 14
days, mice were subjected to longitudinal in vivo bioluminescence imaging using the
Xenogen IVIS 200 Imaging System. Photographs shown are courtesy of Dr. Marion
Zillhardt, University of Chicago.
C) Histological comparison of patient tumor and “xenopatient” graft in the mouse.
Following surgical removal of a serous ovarian tumor, a 1 cm fragment was finely minced
and injected i.p. into SCID/Beige mice. At about 20 weeks, mice were sacrificed and tumors
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collected. Mouse tumor grafts (a,c,e) and patient tumors (b,d,f) were subjected to staining
with hematoxylin and eosin (H&E, a,b), pan-cytokeratin (c,d), or Ki67 (e,f), as indicated.
Photographs shown are courtesy of Saravut John Weroha, Mayo Clinic.
D) Formation of ovarian tumors in LSL-KRasG12D; Ptenfl/fl mice. Tumors were initiated
by injection of adenovirus expressing cre recombinase in the right ovarian bursa. The left
ovary was not injected and served as an internal control. Mice were sacrificed after 8 weeks
and the primary tumor was excised (a), embedded in paraffin, and subjected to staining with
H&E (b). Photographs shown are courtesy of Dr. Iris Romero, University of Chicago.
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FIGURE 3. The domestic egg laying hen model of ovarian cancer
A) Normal ovary of a domestic laying hen. The ovary contains a set of 4 large pre-
ovulatory hierarchical follicles, small developing follicles, and a post-ovulatory follicle.
B) Primary malignant ovarian tumor in laying hen with stage IV OvCa. The tumor was
classified as a serous OvCa on an endometrioid background. The tumor has metastasized to
distant organs with profuse ascites and had an endometrioid histotype. Multiple solid tumor
masses are seen.
C) Histological types of malignant ovarian tumors in hens. (a) Ovarian serous carcinoma
showing sheets of lacelike papillary folding and cells with large pleomorphic nuclei with
mitotic bodies. (b) Ovarian endometrioid carcinoma with confluent back-to-back glands.
Glands contain a single layer of epithelial cells with sharp luminal margin. (c) Ovarian
mucinous carcinoma with crowded glands in clusters without intervening stroma surrounded
by a fibromuscular layer. The epithelium contains columnar and intercalated ciliated goblet
cells. The nuclei are separated from the basement membrane and have moved toward the
apical surface with occasional stratification and luminal secretion. (d) Poorly differentiated
ovarian clear cell carcinoma showing vacuolated cells containing high-grade nuclear atypia
that invade the stroma and theca layer of stromal follicles. Deposition of eosinophilic
hyalinized matrix in the stroma and necrotic bodies are also seen. Hematoxylin and eosin
staining (original magnification 40X).
D) Immunohistochemical localization of E-cadherin expression in human (a,b) and
laying hen (c,d) normal ovarian and cancerous tissue. The uninvolved epithelial cells in
normal human ovarian tissue (a) and in normal laying hen ovarian tissue (c) lack E-cadherin,
while early neoplastic transformation (black arrow) of adjacent ‘normal’ ovarian surface
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epithelial cells and mild to moderate dysplastic cells (white arrow) are marked by an
increase in E-cadherin expression. Tumor cells of a human endometrioid type tumor (b) and
a primary hen tumor (d) express high E-cadherin levels in distinct patterns throughout the
tissue (bar= 50μm).
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